Loading…
Loading…
we were sort of surprised to see that one selected for the Medicare price reductions in 2028
curious your thoughts around updating the Street on sort of your longer-term outlook for Skyrizi and Rinvoq
Wondering if you can just sort of talk about the commercial opportunity for that indication
I thought products like your breast implants and Juvederm may be included right now. So curious if that's the case or not
give a sense of where you think the share is now for Botox and Juvéderm sort of this point in time
comment a little more on pricing dynamics that you're seeing there as to how you've factored in pricing both for this year
Just want any initial feedback you can share with us in terms of the initial launch and what doctors and patients are saying
what initial feedback is from doctors and is this buy and bill model?
your general level of enthusiasm
There's three products that are not on there anymore that were there. At the end of twenty twenty-three
I'm curious how you think about that product sort of in 2026 and beyond, both in the U.S.
has your ex U.S. sort of strategy at all evolved given sort of the threat of most-favored-nation pricing
comment on the sort of environment for business development now given all the macro volatility
Just curious if it's changed in any way your expectations for Cadence. I think that's maybe underappreciated